Key clinical point: A combination of rituximab, bendamustine and cytarabine (R-BAC) may be a treatment option for patients with relapsed/refractory mantle cell lymphoma who experience disease progression on a Bruton’s tyrosine kinase inhibitor (BTKi).

Major finding: The overall response rate to R-BAC was 90.5%.

Study details: A retrospective analysis of 22 patients with relapsed/refractory mantle cell lymphoma (MCL) who received combination therapy with R-BAC after disease progression with a BTKi.

Disclosures: The investigators reported having no conflicts of interest.